Ham Su Jin, Lee Soo Young, Song Saera, Chung Ju-Ryung, Choi Sekyu, Chung Jongkyeong
From the Interdisciplinary Graduate Program in Genetic Engineering,; National Creative Research Initiatives Center for Energy Homeostasis Regulation,; Institute of Molecular Biology and Genetics, and.
National Creative Research Initiatives Center for Energy Homeostasis Regulation,; Institute of Molecular Biology and Genetics, and.
J Biol Chem. 2016 Jan 22;291(4):1803-1816. doi: 10.1074/jbc.M115.687319. Epub 2015 Dec 2.
Parkin is an E3 ligase that contains a ubiquitin-like (UBL) domain in the N terminus and an R1-in-between-ring-RING2 motif in the C terminus. We showed that the UBL domain specifically interacts with the R1 domain and negatively regulates Parkin E3 ligase activity, Parkin-dependent mitophagy, and Parkin translocation to the mitochondria. The binding between the UBL domain and the R1 domain was suppressed by carbonyl cyanide m-chlorophenyl hydrazone treatment or by expression of PTEN-induced putative kinase 1 (PINK1), an upstream kinase that phosphorylates Parkin at the Ser-65 residue of the UBL domain. Moreover, we demonstrated that phosphorylation of the UBL domain at Ser-65 prevents its binding to the R1 domain and promotes Parkin activities. We further showed that mitochondrial translocation of Parkin, which depends on phosphorylation at Ser-65, and interaction between the R1 domain and a mitochondrial outer membrane protein, VDAC1, are suppressed by binding of the UBL domain to the R1 domain. Interestingly, Parkin with missense mutations associated with Parkinson disease (PD) in the UBL domain, such as K27N, R33Q, and A46P, did not translocate to the mitochondria and induce E3 ligase activity by m-chlorophenyl hydrazone treatment, which correlated with the interaction between the R1 domain and the UBL domain with those PD mutations. These findings provide a molecular mechanism of how Parkin recruitment to the mitochondria and Parkin activation as an E3 ubiquitin ligase are regulated by PINK1 and explain the previously unknown mechanism of how Parkin mutations in the UBL domain cause PD pathogenesis.
帕金蛋白是一种E3泛素连接酶,其N端含有一个类泛素(UBL)结构域,C端含有一个R1-中间环-RING2基序。我们发现,UBL结构域与R1结构域特异性相互作用,并负向调节帕金蛋白的E3连接酶活性、帕金蛋白依赖性线粒体自噬以及帕金蛋白向线粒体的转位。羰基氰化物间氯苯腙处理或PTEN诱导的假定激酶1(PINK1,一种上游激酶,可使帕金蛋白UBL结构域的Ser-65残基磷酸化)的表达可抑制UBL结构域与R1结构域之间的结合。此外,我们证明,UBL结构域Ser-65位点的磷酸化可阻止其与R1结构域的结合,并促进帕金蛋白的活性。我们进一步表明,依赖于Ser-65磷酸化的帕金蛋白向线粒体的转位以及R1结构域与线粒体外膜蛋白VDAC1之间的相互作用,会被UBL结构域与R1结构域的结合所抑制。有趣的是,在UBL结构域中具有与帕金森病(PD)相关的错义突变(如K27N、R33Q和A46P)的帕金蛋白,经羰基氰化物间氯苯腙处理后不会转位至线粒体并诱导E3连接酶活性,这与那些PD突变的R1结构域和UBL结构域之间的相互作用相关。这些发现提供了一种分子机制,解释了PINK1如何调节帕金蛋白向线粒体的募集以及帕金蛋白作为E3泛素连接酶的激活,并解释了UBL结构域中的帕金蛋白突变导致PD发病机制的先前未知机制。